Royal Bank of Canada’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-14
| Closed | – | – | 7788 |
|
|
2024
Q1 | $0 | Buy |
14
+11
| +367% | +$27 | ﹤0.01% | 7803 |
|
|
2023
Q4 | $0 | Sell |
3
-23
| -88% | -$41 | ﹤0.01% | 7772 |
|
|
2023
Q3 | $0 | Sell |
26
-479
| -95% | -$1.15K | ﹤0.01% | 7803 |
|
|
2023
Q2 | $2K | Sell |
505
-1,634
| -76% | -$6.3K | ﹤0.01% | 6931 |
|
|
2023
Q1 | $13K | Sell |
2,139
-3,136
| -59% | -$19.1K | ﹤0.01% | 6217 |
|
|
2022
Q4 | $32K | Buy |
5,275
+4,419
| +516% | +$36K | ﹤0.01% | 6114 |
|
|
2022
Q3 | $10K | Buy |
856
+192
| +29% | +$2.51K | ﹤0.01% | 6441 |
|
|
2022
Q2 | $8K | Sell |
664
-1,418
| -68% | -$13.2K | ﹤0.01% | 6489 |
|
|
2022
Q1 | $24K | Sell |
2,082
-3,504
| -63% | -$38.6K | ﹤0.01% | 6519 |
|
|
2021
Q4 | $100K | Buy |
5,586
+1,923
| +52% | +$40.6K | ﹤0.01% | 5943 |
|
|
2021
Q3 | $85K | Buy |
3,663
+1,651
| +82% | +$35.9K | ﹤0.01% | 5828 |
|
|
2021
Q2 | $48K | Buy |
2,012
+224
| +13% | +$5.7K | ﹤0.01% | 6078 |
|
|
2021
Q1 | $56K | Buy |
1,788
+1,288
| +258% | +$44.9K | ﹤0.01% | 5815 |
|
|
2020
Q4 | $20K | Buy |
+500
| New | +$20.1K | ﹤0.01% | 6076 |
|
Royal Bank of Canada's KNTE Position: Q2 2024 in Review
Royal Bank of Canada sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 14 shares.
Royal Bank of Canada first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $100K in Q4 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Royal Bank of Canada reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Royal Bank of Canada sold 14 Kinnate Biopharma Inc. Common Stock shares in Q2 2024.
- Royal Bank of Canada first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
- Royal Bank of Canada's Kinnate Biopharma Inc. Common Stock position peaked at $100K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.